Nicotinamide riboside - Revision history

Fire: Marked this version for translation

2024-04-07T23:19:01Z

Marked this version for translation

← Older revision		Revision as of 08:19, 8 April 2024
Line 1:		Line 1:
	<languages />		<languages />
	<translate>		<translate>
			<!--T:1-->
	{{Chembox		{{Chembox
	\| Name =		\| Name =
Line 108:		Line 109:
	}}		}}

			<!--T:2-->
	'''Nicotinamide riboside''' ('''NR''', '''SR647''') is a [[pyridine]]-[[nucleoside]] and a form of [[Vitamin B3\|vitamin B<sub>3</sub>]]. It functions as a precursor to [[nicotinamide adenine dinucleotide]], or [[NAD+]],		'''Nicotinamide riboside''' ('''NR''', '''SR647''') is a [[pyridine]]-[[nucleoside]] and a form of [[Vitamin B3\|vitamin B<sub>3</sub>]]. It functions as a precursor to [[nicotinamide adenine dinucleotide]], or [[NAD+]],
	through a two-step and a three-step pathway.		through a two-step and a three-step pathway.

	==Chemistry==		==Chemistry== <!--T:3-->
	While the molecular weight of nicotinamide riboside is 255.25 g/mol, that of its chloride salt is 290.70 g/mol. As such, 100 mg of nicotinamide riboside chloride provides 88 mg of nicotinamide riboside.		While the molecular weight of nicotinamide riboside is 255.25 g/mol, that of its chloride salt is 290.70 g/mol. As such, 100 mg of nicotinamide riboside chloride provides 88 mg of nicotinamide riboside.

	==History==		==History== <!--T:4-->
	Nicotinamide riboside (NR) has been identified as an NAD precursor, involved in salvage NAD synthesis in both [[bacteria]] and [[eukaryotes]].		Nicotinamide riboside (NR) has been identified as an NAD precursor, involved in salvage NAD synthesis in both [[bacteria]] and [[eukaryotes]].
	In bacteria, it was first described in 1944 as a necessary growth factor for the culture of ''[[Haemophilus influenza]]'', ''H. influenza'' was identified as requiring both X factor ([[hemin]]) and V factor (NAD) to grow.		In bacteria, it was first described in 1944 as a necessary growth factor for the culture of ''[[Haemophilus influenza]]'', ''H. influenza'' was identified as requiring both X factor ([[hemin]]) and V factor (NAD) to grow.
	V factor, purified from blood, was shown to exist in three forms: [[Nicotinamide adenine dinucleotide]] (NAD+), [[Nicotinamide mononucleotide\|NMN]] and NR. NR was the compound that led to the most rapid growth of the ''H. influenza'' bacterium.		V factor, purified from blood, was shown to exist in three forms: [[Nicotinamide adenine dinucleotide]] (NAD+), [[Nicotinamide mononucleotide\|NMN]] and NR. NR was the compound that led to the most rapid growth of the ''H. influenza'' bacterium.

			<!--T:5-->
	''H. influenza'' cannot grow on [[nicotinic acid]] (NA), [[nicotinamide]] (NAM), or amino acids such as [[tryptophan]] (Trp) or [[aspartic acid]] (Asp), which were the previously known precursors of NAD+.		''H. influenza'' cannot grow on [[nicotinic acid]] (NA), [[nicotinamide]] (NAM), or amino acids such as [[tryptophan]] (Trp) or [[aspartic acid]] (Asp), which were the previously known precursors of NAD+.
	''H. influenza'' depends entirely on salvage of NAD precursors from other cells in its environment.		''H. influenza'' depends entirely on salvage of NAD precursors from other cells in its environment.

			<!--T:6-->
	The identification of Nicotinamide riboside (NR) as an NAD precursor in [[eukaryotes]] developed out of the study of [[pellagra]]. Pellagra was the first disease to be associated with NAD+ deficiency. It was linked to nutritional deficiency by [[Joseph Goldberger]] in 1914, and to deficiency of [[Niacin (substance)\|niacin]] ([[Vitamin B3\|vitamin B<sub>3</sub>]]) by [[Conrad Elvehjem]] in 1937. NAD+ (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD+ levels. Pellagra is now understood as a severe, chronic depletion of NAD+, which can be treated through diet.		The identification of Nicotinamide riboside (NR) as an NAD precursor in [[eukaryotes]] developed out of the study of [[pellagra]]. Pellagra was the first disease to be associated with NAD+ deficiency. It was linked to nutritional deficiency by [[Joseph Goldberger]] in 1914, and to deficiency of [[Niacin (substance)\|niacin]] ([[Vitamin B3\|vitamin B<sub>3</sub>]]) by [[Conrad Elvehjem]] in 1937. NAD+ (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD+ levels. Pellagra is now understood as a severe, chronic depletion of NAD+, which can be treated through diet.

			<!--T:7-->
	Subsequent studies of NAD+ metabolism have identified regulatory pathways used by cells and tissues to maintain NAD+ availability. NAD+ and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular [[Redox\|oxidation/reduction reactions]] and [[Adenosine triphosphate\|ATP]] synthesis. Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step ''de novo'' pathway from Trp and two pathways using the NAD+ precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme [[Nicotinamide phosphoribosyltransferase]] (NAMPT) and the formation of nicotinamide mononucleotide (NMN).		Subsequent studies of NAD+ metabolism have identified regulatory pathways used by cells and tissues to maintain NAD+ availability. NAD+ and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular [[Redox\|oxidation/reduction reactions]] and [[Adenosine triphosphate\|ATP]] synthesis. Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step ''de novo'' pathway from Trp and two pathways using the NAD+ precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme [[Nicotinamide phosphoribosyltransferase]] (NAMPT) and the formation of nicotinamide mononucleotide (NMN).

			<!--T:8-->
	In 2004, a previously unknown pathway was reported when nicotinamide riboside (NR) was identified as an additional NAD+ precursor in [[eukaryotes]].		In 2004, a previously unknown pathway was reported when nicotinamide riboside (NR) was identified as an additional NAD+ precursor in [[eukaryotes]].
	NR is now recognized as a form of [[Vitamin B3\|vitamin B<sub>3</sub>]] which can be found in both cow and human milk.		NR is now recognized as a form of [[Vitamin B3\|vitamin B<sub>3</sub>]] which can be found in both cow and human milk.
	Once internalized into a cell, NR is rapidly phosphorylated by the activity of nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), bypassing the previously known biosynthetic routes to NAD+ production. NMN is then converted to NAD+ by NMN-adenylyltransferase (NMNAT).		Once internalized into a cell, NR is rapidly phosphorylated by the activity of nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), bypassing the previously known biosynthetic routes to NAD+ production. NMN is then converted to NAD+ by NMN-adenylyltransferase (NMNAT).

			<!--T:9-->
	Research in mammals indicates that NRK1 is a cytosolic protein, encoded by the ''Nmrk1'' gene. It is found in most tissues but predominantly in the liver and kidney. The NRK2 protein may be related to muscle tissue including cardiac muscle. It is encoded by the ''Nmrk2'' gene and appears to be more highly expressed in cases of metabolic stress or cellular damage.		Research in mammals indicates that NRK1 is a cytosolic protein, encoded by the ''Nmrk1'' gene. It is found in most tissues but predominantly in the liver and kidney. The NRK2 protein may be related to muscle tissue including cardiac muscle. It is encoded by the ''Nmrk2'' gene and appears to be more highly expressed in cases of metabolic stress or cellular damage.
	Since different types of tissues display differing concentrations of NR and NRKs, it is likely that NR utilization will vary in different tissues.		Since different types of tissues display differing concentrations of NR and NRKs, it is likely that NR utilization will vary in different tissues.

			<!--T:10-->
	Metabolic studies indicate that NAD+, once considered a stable molecule, is continuously turned over and used, requiring tight regulation to maintain metabolic homeostasis. NR utilization in mammals may involve both exogenous dietary sources and endogenous salvage processes that recycle intermediates. NR metabolism and the interactions of different NAD+ pathways continue to be studied. The NAM and NR pathways involve an amide group and are referred to as ‘amidated’ pathways. The pathways for ''de novo'' synthesis from tryptophan and from NA salvage are ‘deamidated’ pathways, which share a rate-limiting amidation enzyme NADsynthase1 (NADSYN). Disruptions or imbalances in NAD+ metabolism have been observed in many disease conditions, and the possibility of restoring NAD+ levels by administering NAD+ precursors is an area of interest for researchers.		Metabolic studies indicate that NAD+, once considered a stable molecule, is continuously turned over and used, requiring tight regulation to maintain metabolic homeostasis. NR utilization in mammals may involve both exogenous dietary sources and endogenous salvage processes that recycle intermediates. NR metabolism and the interactions of different NAD+ pathways continue to be studied. The NAM and NR pathways involve an amide group and are referred to as ‘amidated’ pathways. The pathways for ''de novo'' synthesis from tryptophan and from NA salvage are ‘deamidated’ pathways, which share a rate-limiting amidation enzyme NADsynthase1 (NADSYN). Disruptions or imbalances in NAD+ metabolism have been observed in many disease conditions, and the possibility of restoring NAD+ levels by administering NAD+ precursors is an area of interest for researchers.

	==Biosynthesis==		==Biosynthesis== <!--T:11-->
	{{Main\|Nicotinamide adenine dinucleotide#Biosynthesis}}		{{Main\|Nicotinamide adenine dinucleotide#Biosynthesis}}

			<!--T:12-->
	Nicotinamide riboside (NR) is now known to be an NAD+ precursor, involved in the biosynthetic pathways that convert B3 vitamins into NAD+. NAD+ is primarily synthesized in mammals de novo from tryptophan, through the Priess-Handler pathway from nicotinic acid (NA) or via a salvage pathway from nicotinamide (NAM).		Nicotinamide riboside (NR) is now known to be an NAD+ precursor, involved in the biosynthetic pathways that convert B3 vitamins into NAD+. NAD+ is primarily synthesized in mammals de novo from tryptophan, through the Priess-Handler pathway from nicotinic acid (NA) or via a salvage pathway from nicotinamide (NAM).

			<!--T:13-->
	[[File:NRK1 and NRK2 mediated biosynthesis pathway from NR to NAD+.png \|450px\|thumb\|center\|NRK1/2 mediated pathway from NR to NAD+]]		[[File:NRK1 and NRK2 mediated biosynthesis pathway from NR to NAD+.png \|450px\|thumb\|center\|NRK1/2 mediated pathway from NR to NAD+]]

			<!--T:14-->
	Nicotinamide riboside (NR) is utilized through an additional pathway involving phosphorylation by the nicotinamide riboside kinase enzymes (NRK1 and NRK2). In yeasts, NR has also been shown to be degraded by the nucleosidases Pnp1, Urh1 and Meu1, before being converted to NAD⁺ via the Preiss-Handler pathway and the action of the nicotinamidase Pnc1.		Nicotinamide riboside (NR) is utilized through an additional pathway involving phosphorylation by the nicotinamide riboside kinase enzymes (NRK1 and NRK2). In yeasts, NR has also been shown to be degraded by the nucleosidases Pnp1, Urh1 and Meu1, before being converted to NAD⁺ via the Preiss-Handler pathway and the action of the nicotinamidase Pnc1.

	==Commercialization==		==Commercialization== <!--T:15-->
	[[ChromaDex]] licensed patents in July 2012, and began to develop a process to bring NR to market as TruNiagen. ChromaDex has been in a patent dispute with [[Elysium Health]] over the rights to nicotinamide riboside supplements since 2016.		[[ChromaDex]] licensed patents in July 2012, and began to develop a process to bring NR to market as TruNiagen. ChromaDex has been in a patent dispute with [[Elysium Health]] over the rights to nicotinamide riboside supplements since 2016.

	==Safety designations==		==Safety designations== <!--T:16-->
	In 2016, the U.S. Food and Drug Administration (FDA) has granted [[Generally recognized as safe]] (GRAS) status to ChromaDex for its preparation of nicotinamide riboside chloride (NRC, Niagen™). It was designated a new dietary ingredient (NDI) for use in dietary supplements by the U.S. Food and Drug Administration in 2015 and 2017. It was listed in Health Canada's Licensed Natural Health Products Database (LNHPD) in 2018. The European Union has granted NRC a "New dietary ingredient" designation as a novel food pursuant to Regulation (EU) 2015/2283, as of 2019. It was authorized for use in food supplements by the EU in 2020. The EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) considered it as safe as pure nicotinamide for use in food for special medical purposes (FSMP) and total diet replacement for weight control (TDRWC) in adults as of 2021 but noted that further investigation would be required to establish safety for some other types of use.		In 2016, the U.S. Food and Drug Administration (FDA) has granted [[Generally recognized as safe]] (GRAS) status to ChromaDex for its preparation of nicotinamide riboside chloride (NRC, Niagen™). It was designated a new dietary ingredient (NDI) for use in dietary supplements by the U.S. Food and Drug Administration in 2015 and 2017. It was listed in Health Canada's Licensed Natural Health Products Database (LNHPD) in 2018. The European Union has granted NRC a "New dietary ingredient" designation as a novel food pursuant to Regulation (EU) 2015/2283, as of 2019. It was authorized for use in food supplements by the EU in 2020. The EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) considered it as safe as pure nicotinamide for use in food for special medical purposes (FSMP) and total diet replacement for weight control (TDRWC) in adults as of 2021 but noted that further investigation would be required to establish safety for some other types of use.
	The Australian government has given nicotinamide riboside chloride a positive listing under the compositional guidelines of its Therapeutic Goods Administration (TGA).		The Australian government has given nicotinamide riboside chloride a positive listing under the compositional guidelines of its Therapeutic Goods Administration (TGA).

	== See also ==		== See also == <!--T:17-->
	* [[Nicotinamide mononucleotide]]		* [[Nicotinamide mononucleotide]]
	* [[Niacin (substance)\|Niacin]]		* [[Niacin (substance)\|Niacin]]
Line 160:		Line 171:
	* [[Poly (ADP-ribose) polymerase]]		* [[Poly (ADP-ribose) polymerase]]

			<!--T:18-->
	{{二次利用\|date=20 March 2024}}		{{二次利用\|date=20 March 2024}}
	[[Category:Ribosides]]		[[Category:Ribosides]]
	[[Category:Nicotinamides]]		[[Category:Nicotinamides]]
	</translate>		</translate>

Fire at 23:18, 7 April 2024

2024-04-07T23:18:43Z

← Older revision		Revision as of 08:18, 8 April 2024
Line 1:		Line 1:
			<languages />
			<translate>
	{{Chembox		{{Chembox
	\| Name =		\| Name =
Line 161:		Line 163:
	[[Category:Ribosides]]		[[Category:Ribosides]]
	[[Category:Nicotinamides]]		[[Category:Nicotinamides]]
			</translate>

Fire: /* History */

2024-04-07T05:22:05Z

History

← Older revision		Revision as of 14:22, 7 April 2024
Line 120:		Line 120:
	''H. influenza'' depends entirely on salvage of NAD precursors from other cells in its environment.		''H. influenza'' depends entirely on salvage of NAD precursors from other cells in its environment.

	The identification of Nicotinamide riboside (NR) as an NAD precursor in [[eukaryotes]] developed out of the study of [[pellagra]].~~<ref name="pmid35918544"/>~~ Pellagra was the first disease to be associated with NAD+ deficiency. It was linked to nutritional deficiency by [[Joseph Goldberger]] in 1914, and to deficiency of [[Niacin (substance)\|niacin]] ([[Vitamin B3\|vitamin B<sub>3</sub>]]) by [[Conrad Elvehjem]] in 1937. NAD+ (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD+ levels. Pellagra is now understood as a severe, chronic depletion of NAD+, which can be treated through diet.		The identification of Nicotinamide riboside (NR) as an NAD precursor in [[eukaryotes]] developed out of the study of [[pellagra]]. Pellagra was the first disease to be associated with NAD+ deficiency. It was linked to nutritional deficiency by [[Joseph Goldberger]] in 1914, and to deficiency of [[Niacin (substance)\|niacin]] ([[Vitamin B3\|vitamin B<sub>3</sub>]]) by [[Conrad Elvehjem]] in 1937. NAD+ (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD+ levels. Pellagra is now understood as a severe, chronic depletion of NAD+, which can be treated through diet.

	Subsequent studies of NAD+ metabolism have identified regulatory pathways used by cells and tissues to maintain NAD+ availability. NAD+ and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular [[Redox\|oxidation/reduction reactions]] and [[Adenosine triphosphate\|ATP]] synthesis. Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step ''de novo'' pathway from Trp and two pathways using the NAD+ precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme [[Nicotinamide phosphoribosyltransferase]] (NAMPT) and the formation of nicotinamide mononucleotide (NMN).		Subsequent studies of NAD+ metabolism have identified regulatory pathways used by cells and tissues to maintain NAD+ availability. NAD+ and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular [[Redox\|oxidation/reduction reactions]] and [[Adenosine triphosphate\|ATP]] synthesis. Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step ''de novo'' pathway from Trp and two pathways using the NAD+ precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme [[Nicotinamide phosphoribosyltransferase]] (NAMPT) and the formation of nicotinamide mononucleotide (NMN).

Fire: Created page with "{{Chembox | Name = | ImageFile = nicotinamide-beta-riboside.svg | ImageAlt = | ImageCaption = | ImageFile1 = Nicotinamideriboside.png | ImageAlt1 = | ImageCaption1 = | IUPACName = 3-Carbamoyl-1-(β-D-ribofuranosyl)pyridin-1-ium | SystematicName = 3-Carbamoyl-1-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium | OtherNames = 1-(β-D-Ribofuranosyl)nicotinamide; ''N''-Ribosylnicotinamide |Section1={{Che..."

2024-04-07T05:20:29Z

Created page with "{{Chembox | Name = | ImageFile = nicotinamide-beta-riboside.svg | ImageAlt = | ImageCaption = | ImageFile1 = Nicotinamideriboside.png | ImageAlt1 = | ImageCaption1 = | IUPACName = 3-Carbamoyl-1-(β-D-ribofuranosyl)pyridin-1-ium | SystematicName = 3-Carbamoyl-1-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium | OtherNames = 1-(β-D-Ribofuranosyl)nicotinamide; ''N''-Ribosylnicotinamide |Section1={{Che..."

New page

{{Chembox
| Name =
| ImageFile = nicotinamide-beta-riboside.svg
| ImageAlt =
| ImageCaption =
| ImageFile1 = Nicotinamideriboside.png
| ImageAlt1 =
| ImageCaption1 =
| IUPACName = 3-Carbamoyl-1-(β-D-ribofuranosyl)pyridin-1-ium
| SystematicName = 3-Carbamoyl-1-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium
| OtherNames = 1-(β-D-Ribofuranosyl)nicotinamide; ''N''-Ribosylnicotinamide
|Section1={{Chembox Identifiers
| Abbreviations =
| CASNo = 1341-23-7
| CASNo_Comment =
| CASNo_Ref = {{cascite|correct|CAS}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0I8H2M0L7N
| CASNoOther =
| PubChem = 439924
| PubChem_Comment =
| PubChem5 =
| PubChem5_Comment =
| PubChemOther =
| ChemSpiderID = 388956
| ChemSpiderID_Comment =
| ChemSpiderID5 =
| ChemSpiderIDOther =
| EINECS =
| EC_number =
| UNNumber =
| DrugBank =
| MeSHName =
| ChEBI = 15927
| RTECS =
| SMILES = c1cc(c[n+](c1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
| StdInChI = 1S/C11H14N2O5/c12-10(17)6-2-1-3-13(4-6)11-9(16)8(15)7(5-14)18
| Beilstein =
| Gmelin =
| 3DMet = }}
|Section2={{Chembox Properties
| Formula = C11H15N2O5+
| MolarMass = 255.25 g/mol
| Appearance =
| Density =
| MeltingPt =
| MeltingPt_notes =
| BoilingPt =
| BoilingPt_notes =
| LogP =
| VaporPressure =
| HenryConstant =
| AtmosphericOHRateConstant =
| pKa =
| pKb =
| Solubility =
| SolubleOther =
| Solvent = }}
|Section3={{Chembox Structure
| CrystalStruct =
| Coordination =
| MolShape = }}
|Section4={{Chembox Thermochemistry
| DeltaHc =
| DeltaHf =
| Entropy =
| HeatCapacity = }}
|Section5={{Chembox Pharmacology
| AdminRoutes =
| Bioavail =
| Metabolism =
| HalfLife =
| ProteinBound =
| Excretion =
| Legal_status =
| Legal_US =
| Legal_UK =
| Legal_AU =
| Legal_CA =
| Pregnancy_category =
| Pregnancy_AU =
| Pregnancy_US = }}
|Section6={{Chembox Explosive
| ShockSens =
| FrictionSens =
| DetonationV =
| REFactor = }}
|Section7={{Chembox Hazards
| ExternalSDS =
| MainHazards =
| NFPA-H =
| NFPA-F =
| NFPA-R =
| NFPA-S =
| FlashPt =
| AutoignitionPt =
| ExploLimits =
| LD50 =
| PEL = }}
|Section8={{Chembox Related
| OtherAnions =
| OtherCations =
| OtherFunction =
| OtherFunction_label =
| OtherCompounds = }}
}}

'''Nicotinamide riboside''' ('''NR''', '''SR647''') is a [[pyridine]]-[[nucleoside]] and a form of [[Vitamin B3|vitamin B3]]. It functions as a precursor to [[nicotinamide adenine dinucleotide]], or [[NAD+]],
through a two-step and a three-step pathway.

==Chemistry==
While the molecular weight of nicotinamide riboside is 255.25 g/mol, that of its chloride salt is 290.70 g/mol. As such, 100 mg of nicotinamide riboside chloride provides 88 mg of nicotinamide riboside.

==History==
Nicotinamide riboside (NR) has been identified as an NAD precursor, involved in salvage NAD synthesis in both [[bacteria]] and [[eukaryotes]].
In bacteria, it was first described in 1944 as a necessary growth factor for the culture of ''[[Haemophilus influenza]]'', ''H. influenza'' was identified as requiring both X factor ([[hemin]]) and V factor (NAD) to grow.
V factor, purified from blood, was shown to exist in three forms: [[Nicotinamide adenine dinucleotide]] (NAD+), [[Nicotinamide mononucleotide|NMN]] and NR. NR was the compound that led to the most rapid growth of the ''H. influenza'' bacterium.

''H. influenza'' cannot grow on [[nicotinic acid]] (NA), [[nicotinamide]] (NAM), or amino acids such as [[tryptophan]] (Trp) or [[aspartic acid]] (Asp), which were the previously known precursors of NAD+.
''H. influenza'' depends entirely on salvage of NAD precursors from other cells in its environment.

The identification of Nicotinamide riboside (NR) as an NAD precursor in [[eukaryotes]] developed out of the study of [[pellagra]].<ref name="pmid35918544"/> Pellagra was the first disease to be associated with NAD+ deficiency. It was linked to nutritional deficiency by [[Joseph Goldberger]] in 1914, and to deficiency of [[Niacin (substance)|niacin]] ([[Vitamin B3|vitamin B3]]) by [[Conrad Elvehjem]] in 1937. NAD+ (then called coenzyme I) was shown to be extremely low in cases of pellagra, and NA and NAM were identified as molecular precursors in rebuilding NAD+ levels. Pellagra is now understood as a severe, chronic depletion of NAD+, which can be treated through diet.

Subsequent studies of NAD+ metabolism have identified regulatory pathways used by cells and tissues to maintain NAD+ availability. NAD+ and its precursors nicotinic acid (NA) and nicotinamide (NAM) have been shown to be vital cofactors in cellular [[Redox|oxidation/reduction reactions]] and [[Adenosine triphosphate|ATP]] synthesis. Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step ''de novo'' pathway from Trp and two pathways using the NAD+ precursors NA and NAM: a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme [[Nicotinamide phosphoribosyltransferase]] (NAMPT) and the formation of nicotinamide mononucleotide (NMN).

In 2004, a previously unknown pathway was reported when nicotinamide riboside (NR) was identified as an additional NAD+ precursor in [[eukaryotes]].
NR is now recognized as a form of [[Vitamin B3|vitamin B3]] which can be found in both cow and human milk.
Once internalized into a cell, NR is rapidly phosphorylated by the activity of nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), bypassing the previously known biosynthetic routes to NAD+ production. NMN is then converted to NAD+ by NMN-adenylyltransferase (NMNAT).

Research in mammals indicates that NRK1 is a cytosolic protein, encoded by the ''Nmrk1'' gene. It is found in most tissues but predominantly in the liver and kidney. The NRK2 protein may be related to muscle tissue including cardiac muscle. It is encoded by the ''Nmrk2'' gene and appears to be more highly expressed in cases of metabolic stress or cellular damage.
Since different types of tissues display differing concentrations of NR and NRKs, it is likely that NR utilization will vary in different tissues.

Metabolic studies indicate that NAD+, once considered a stable molecule, is continuously turned over and used, requiring tight regulation to maintain metabolic homeostasis. NR utilization in mammals may involve both exogenous dietary sources and endogenous salvage processes that recycle intermediates. NR metabolism and the interactions of different NAD+ pathways continue to be studied. The NAM and NR pathways involve an amide group and are referred to as ‘amidated’ pathways. The pathways for ''de novo'' synthesis from tryptophan and from NA salvage are ‘deamidated’ pathways, which share a rate-limiting amidation enzyme NADsynthase1 (NADSYN). Disruptions or imbalances in NAD+ metabolism have been observed in many disease conditions, and the possibility of restoring NAD+ levels by administering NAD+ precursors is an area of interest for researchers.

==Biosynthesis==
{{Main|Nicotinamide adenine dinucleotide#Biosynthesis}}

Nicotinamide riboside (NR) is now known to be an NAD+ precursor, involved in the biosynthetic pathways that convert B3 vitamins into NAD+. NAD+ is primarily synthesized in mammals de novo from tryptophan, through the Priess-Handler pathway from nicotinic acid (NA) or via a salvage pathway from nicotinamide (NAM).

[[File:NRK1 and NRK2 mediated biosynthesis pathway from NR to NAD+.png |450px|thumb|center|NRK1/2 mediated pathway from NR to NAD+]]

Nicotinamide riboside (NR) is utilized through an additional pathway involving phosphorylation by the nicotinamide riboside kinase enzymes (NRK1 and NRK2). In yeasts, NR has also been shown to be degraded by the nucleosidases Pnp1, Urh1 and Meu1, before being converted to NAD⁺ via the Preiss-Handler pathway and the action of the nicotinamidase Pnc1.

==Commercialization==
[[ChromaDex]] licensed patents in July 2012, and began to develop a process to bring NR to market as TruNiagen. ChromaDex has been in a patent dispute with [[Elysium Health]] over the rights to nicotinamide riboside supplements since 2016.

==Safety designations==
In 2016, the U.S. Food and Drug Administration (FDA) has granted [[Generally recognized as safe]] (GRAS) status to ChromaDex for its preparation of nicotinamide riboside chloride (NRC, Niagen™). It was designated a new dietary ingredient (NDI) for use in dietary supplements by the U.S. Food and Drug Administration in 2015 and 2017. It was listed in Health Canada's Licensed Natural Health Products Database (LNHPD) in 2018. The European Union has granted NRC a "New dietary ingredient" designation as a novel food pursuant to Regulation (EU) 2015/2283, as of 2019. It was authorized for use in food supplements by the EU in 2020. The EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) considered it as safe as pure nicotinamide for use in food for special medical purposes (FSMP) and total diet replacement for weight control (TDRWC) in adults as of 2021 but noted that further investigation would be required to establish safety for some other types of use.
The Australian government has given nicotinamide riboside chloride a positive listing under the compositional guidelines of its Therapeutic Goods Administration (TGA).

== See also ==
* [[Nicotinamide mononucleotide]]
* [[Niacin (substance)|Niacin]]
* [[Nicotinamide]]
* [[Vitamin B3]]
* [[Nicotinamide adenine dinucleotide]]
* [[Sirtuin]]
* [[Poly (ADP-ribose) polymerase]]

{{二次利用|date=20 March 2024}}
[[Category:Ribosides]]
[[Category:Nicotinamides]]